ArticleMolecular genetics & genomic medicine2020
Plasma-based microRNA signatures in early diagnosis of breast cancer.
Article in Molecular genetics & genomic medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- MicroRNA Dysregulation in Early Breast Cancer Diagnosis: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2023Pooled it
- The assessment of breast cancer biomarkers in diagnosis, prognosis and treatment monitoring: integrated analysis.Journal of cancer research and clinical oncology · 2025Review
- The role of circRNAs and miRNAs in drug resistance and targeted therapy responses in breast cancer.Cancer drug resistance (Alhambra, Calif.) · 2024Review
- Therapeutic potential of miRNAs in placental extracellular vesicles in ovarian and endometrial cancer.Human cell · 2024Article
- Associations of plasma extracellular microRNAs with new-onset breast cancer in the Framingham heart study.American journal of cancer research · 2024Article
- Periconceptional and Prenatal Exposure to Metals and Extracellular Vesicle and Particle miRNAs in Human Milk: A Pilot Study.Exposure and health · 2023Article
- Unraveling the Potential of miRNAs from CSCs as an Emerging Clinical Tool for Breast Cancer Diagnosis and Prognosis.International journal of molecular sciences · 2023Review
- Circulating miRNAs signature on breast cancer: the MCC-Spain project.European journal of medical research · 2023Article
- In Vitro microRNA Expression Profile Alterations under CDK4/6 Therapy in Breast Cancer.Biomedicines · 2023Article
- Article
- Omics-Based Investigations of Breast Cancer.Molecules (Basel, Switzerland) · 2023Review
- Value of Molybdenum Target X-Ray and High-Frequency Color Doppler Flow Imaging in Early Diagnosis of Breast Carcinoma: A Comparative Analysis.Cancer management and research · 2023Article
- Article
- Mir-29b in Breast Cancer: A Promising Target for Therapeutic Approaches.Diagnostics (Basel, Switzerland) · 2022Review
- Modulatory role of miRNAs in thyroid and breast cancer progression and insights into their therapeutic manipulation.Current research in pharmacology and drug discovery · 2022Review
- Cancer Biomarkers in Liquid Biopsy for Early Detection of Breast Cancer: A Systematic Review.Clinical Medicine Insights. Oncology · 2022Review
- Evaluation of Serum MicroRNAs (miR-9-5p, miR-17-5p, and miR-148a-3p) as Potential Biomarkers of Breast Cancer.BioMed research international · 2022Article
- Diagnostic and Prognostic Potential of MiR-379/656 MicroRNA Cluster in Molecular Subtypes of Breast Cancer.Journal of clinical medicine · 2021Article
- Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer.Cancers · 2021Article
- A Signature of Four Circulating microRNAs as Potential Biomarkers for Diagnosing Early-Stage Breast Cancer.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNAs (miRNAs) play an important role in the development and progression of breast cancer (BC). The purpose of the present study was to identify plasma miRNAs enabling early diagnosis of BC. MATERIALS AND
methodsExpression levels of seven plasma miRNAs (miR-23a-3p, miR-29b-2-5p, miR-130a-5p, miR-144-3p, miR-148a-3p, miR-152-3p, and miR-182-5p) in 106 patients with newly diagnosed BC and 96 healthy participants were analyzed by qRT-PCR. We also evaluated the relationship between the expression levels of these miRNAs and clinicopathological features of patients with BC.
resultsCompared with healthy controls, we found that miR-23a-3p (p = .025), miR-130a-5p (p = .006), miR-144-3p (p = .040), miR-148a-3p (p = .023), and miR-152-3p (p = .019) were downregulated in the plasma of patients with BC. MiR-130a-5p, miR-144-3p, and miR-152-3p were downexpressed in BC tissues as well as plasma. The expression of the miR-23a-3p, miR-144-3p, and miR-152-3p was related to ER positive and PR positive. Besides, miR-23a-3p, miR-144-3p, and miR-152-3p did show the significant difference in the staging compromised to the control, especially in stage I-II. Moreover, we also found that miR-144-3p and miR-148a-3p were associated with lymph node invasion.
conclusionsThe expression levels of the miR-23a-3p, miR-130a-5p, miR-144-3p, miR-148a-3p, and miR-152-3p were lower in patients with BC compared to healthy controls and were associated with ex hormone receptor, clinical stage, and lymph node metastasis, indicating the diagnostic potential of these miRNAs in BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.